Rebiopsying for Prostate Cancer
E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses rebiopsying for prostate cancer.
E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses rebiopsying for prostate cancer.
Clinical Pearls:
- Each year in the U.S., 1.3-1.4 million biopsies are performed for prostate cancer, with only 240,000 leading to diagnoses
- The need for a test to determine which men should be rebiopsied may have been answered by the ConfirmMDx test
- Methylation tests look for DNA changes in normal tissue on a biopsy that potentially was around the cancer
- If the test is negative and no genes are methylated, the physician is presented with a 90%-plus positive predictive value that the man does not have cancer. If the test is negative and the man does have cancer, it is typically low-grade and would not be treated anyway.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
FPI-2265 Dosing Commences in Phase 2 AlphaBreak Trial for mCRPC
May 10th 2024The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.
Read More
